


Amendments to the Claims:

The following listing of claims replaces all prior versions, and listings, of claims in the application:

Listing of Claims:

1-14. (canceled)

15. (previously presented) A compound corresponding to formula (I) or a pharmaceutically acceptable salt or isomer thereof:









wherein:

A is CONH, NHCO, NHC(=S)NH, or NHC(=O)NH;

R₁ to R₄ is independently a hydrogen, halogen atom, cyano group, nitro group, lower alkyl amine, lower alkoxy group having 1 to 3 carbon atoms, carboxylic acid, hydroxamic acid, alkyl ester group having 1 to 6 carbon atoms, alkyl amide group having 1 to 6 carbon atoms, benzylamide group, or a 5 or 6-member heterocyclic ring;

R₅ and R₆ are independently a hydrogen, hydroxyl group, amino group, straight or branched alkyl group having 1 to 6 carbon atoms, a cycloalkyl group having 1 to 6 carbon atoms, or a phenyl or benzyl group optionally substituted with at least one substituent selected from the group consisting of halogen atom, an amine group, and an alkyl group having 1 to 6 carbon atoms, provided that both of R₅ and R₆ are not hydrogen atoms simultaneously;

B is a group selected from




in which R_7 to R_{17} is independently a hydrogen atom, a halogen atom, or a straight or branched alkyl group having 1 to 6 carbon atoms optionally substituted with more than one halogen atom;

C is an alkyl, alkenyl, or alkynyl group having 1 to 5 carbon atoms which may include one or more heteroatoms, wherein each of m , n , p , q , r , and s is an integer of 0 to 3; and

an asteric mark * indicates a chiral carbon atom; and
(-----) mark indicates a double bond or single bond chain.

16. (previously presented) A compound according to claim 15, corresponding to formula (II) or a pharmaceutically acceptable salt or isomer thereof:



wherein,

R₁ to R₄ is independently a hydrogen, halogen atom, cyano group, nitro group, lower alkyl amine, lower alkoxy group having 1 to 3 carbon atoms, carboxylic acid, hydroxamic acid, alkyl ester group having 1 to 6 carbon atoms, alkyl amide group having 1 to 6 carbon atoms, benzylamide group, or a five or six-member heterocyclic ring; and

R₅ and R₆ are independently a hydrogen, hydroxyl group, amino group, straight or branched alkyl group having 1 to 6 carbon atoms, cycloalkyl group having 1 to 6 carbon atoms or a phenyl or benzyl group optionally substituted with at least one substituent selected from the group consisting of halogen atom, amine group and alkyl group having 1 to 6 carbon, provided that both of R₅ and R₆ are not hydrogen simultaneously

17. (previously presented) A compound according to claim 16, wherein said compound is at least one selected from the group consisting of:

N-(4-tert-butylbenzyl)-2-[3-fluoro-4-(methanesulfonylamino)phenyl]propionamide
(1-51, KMJ-372),

N-(4-tert-butylbenzyl)-2-[3-chloro-4-(methanesulfonylamino)phenyl]propionamide
(1-52, KMJ-470),

N-(4-tert-butylbenzyl)-2-[3-bromo-4-(methylsulfonylamino)phenyl]propionamide (1-53,SH-173),
N-(4-tert-butylbenzyl)-2-[3-iodo-4-(methylsulfonylamino)phenyl]propionamide (1-54,SH-168),
N-(4-tert-butylbenzyl)-2-[3,5-difluoro-4-(methylsulfonylamino)phenyl]-propionamide (1-55,SH-285),
N-(4-tert-butylbenzyl)-2-[3-cyano-4-(methylsulfonylamino)phenyl]propionamide (1-56,SH-219),
N-(4-tert-butylbenzyl)-2-[3-methoxycarbonyl-4-(methylsulfonylamino)phenyl]-propionamide (1-57, JMJ-806),
N-(4-tert-butylbenzyl)-2-[3-carboxyl-4-(methylsulfonylamino)phenyl]-propionamide (1-58, KMJ-788),
N-(4-tert-butylbenzyl)-2-[3-methoxycarbonyl-4-(methylsulfonylamino)phenyl]-propionamide (1-59,KMJ-838),
N-(4-tert-butylbenzyl)-2-[3-(benzylamino)carbonyl-4-(methylsulfonylamino)-phenyl]propionamide (1-60,KMJ-836),
N-(4-tert-butylbenzyl)-2-[3-piperidino-4-(methylsulfonylamino)phenyl]-propionamide (1-61,YS-65),
N-(4-tert-butylbenzyl)-2-[3-morpholino-4-(methylsulfonylamino)phenyl]-propionamide (1-62,YS-49),
N-(4-tert-butylbenzyl)-2-[3-(N-Boc)piperazino-4-(methylsulfonylamino)phenyl]-propionamide (1-63,YS-76),
N-(4-tert-butylbenzyl)-2-[3-piperazino-4-(methylsulfonylamino)phenyl]-propionamide (1-64,YS-79),
N-(4-tert-butylbenzyl)-2-[3-methoxy-4-(methylsulfonylamino)phenyl]-propionamide (1-65,CHK-717),
N-(4-tert-butylbenzyl)-2-[2-fluoro-4-(methylsulfonylamino)phenyl]propionamide (1-66,KMJ-708),
N-(4-tert-butylbenzyl)-2-[2-chloro-4-(methylsulfonylamino)phenyl]propionamide (1-67,KMJ-698),

N-(4-tert-butylbenzyl)-2-[4-(methylsulfonylamino)phenyl]propionamide
(2-7, KMJ-750),
N-(4-chloro)-2-[4-(methylsulfonylamino)phenyl]propionamide (2-8, YS-85),
N-(3,4-dichloro)-2-[4-(methylsulfonylamino)phenyl]propionamide (2-9, YS-97),
N-(4-tert-butylbenzyl)-(2S)-2-[3-fluoro-4-(methylsulfonylamino)phenyl]-
propionamide (3-5, SU-834),
N-(4-tert-butylbenzyl)-(2R)-2-[3-fluoro-4-(methylsulfonylamino)phenyl]-
propionamide (3-6, SU-824),
N-(4-chlorobenzyl)-2-[3-fluoro-4-(methylsulfonylamino)phenyl]propionamide
(4-1, SH-291),
N-(4-chlorobenzyl)-2-[3-chloro-4-(methylsulfonylamino)phenyl]propionamide
(4-2, SH-290),
N-(4-chlorobenzyl)-2-[3-bromo-4-(methylsulfonylamino)phenyl]propionamide
(4-3, SH-335),
N-(3,4-dichlorobenzyl)-2-[3-fluoro-4-(methylsulfonylamino)phenyl]propionamide
(4-4, SH-94),
N-(3,4-dichlorobenzyl)-2-[3-chloro-4-(methylsulfonylamino)phenyl]propionamide
(4-5, SH-286),
N-(3,4-dichlorobenzyl)-2-[3-bromo-4-(methylsulfonylamino)phenyl]propionamide
(4-6, SH-337),
N-(4-methylbenzyl)-2-[3-fluoro-4-(methylsulfonylamino)phenyl]propionamide
(4-7, SH-351),
N-(4-isopropylbenzyl)-2-[3-fluoro-4-(methylsulfonylamino)phenyl]propionamide
(4-8, KMJ-928),
N-(4-methoxybenzyl)-2-[3-fluoro-4-(methylsulfonylamino)phenyl]propionamide
(4-9, SH-353),
N-(4-trifluoromethylbenzyl)-2-[3-fluoro-4-(methylsulfonylamino)phenyl]-
propionamide (4-10, SH-93),
N-(4-phenylbenzyl)-2-(3-fluoro-4-(methylsulfonylamino)phenyl]propionamide
(4-11, KMJ-498),


N-(1-naphthylmethyl)-[3-fluoro-4-(methylsulfonylamino)phenyl]propionamide
(4-12, SH-92),
N-(1,2,3,4-tetrahydro-1-naphthalenyl)-2-[3-fluoro-4-methylsulfonylamino)phenyl]-
propionamide (4-13, SH-112),
N-[2-(4-tert-butylphenyl)ethy]-2-[3-fluoro-4-(methylsulfonylamino)phenyl]-
propionamide (4-14, KMJ-374),
N-[3-(3,4-dimethylphenyl)propyl]-2-[3-fluoro-4-methylsulfonylamino)phenyl]-
propionamide (4-15, SU-770),
N-[3-(3,4-dimethylphenyl)propyl]-(2R)-2-[3-fluoro-4-methylsulfonylamino)-
phenyl]propionamide (4-16, SU-774),
N-[3-(3,4-dimethylphenyl)propyl]-(2S)-2-[3-fluoro-4-methylsulfonylamino)-
phenyl]propionamide (4-17, SU-776),
N-[3-(3,4-dimethylphenyl)-2-propenyl]-2-[3-fluoro-4-(methylsulfonylamino)-
phenyl]propionamide (4-18, KMJ-686),
N-[3-(4-chlorophenyl)propyl]-2-[3-fluoro-4-methylsulfonylamino)phenyl]-
propionamide (4-19, KMJ-518),
N-[3-(4-chlorophenyl)-2-propenyl]-2-[3-fluoro-4-methylsulfonylamino)phenyl]-
propionamide (4-20, KMJ-732),
N-benzyloxy-2-[3-fluoro-4-(methylsulfonylamino)phenyl]propionamide (4-21, SH-
109),
N-(benzhydryl)-2-[3-fluoro-4-(methylsulfonylamino)phenyl]propionamide
(4-22, SH-130),
N-(2,2-diphenylethyl)-2-[3-fluoro-4-(methylsulfonylamino)phenyl]propionamide
(4-23, SH-116),
N-(3,3-diphenylpropyl)-2-[3-fluoro-4-(methylsulfonylamino)phenyl]propionamide
(4-24, KMJ-378),
N-(3,3-diphenyl-2-propenyl)-2-[3-fluoro-4-methylsulfonylamino)phenyl]-
propionamide (4-25, KMJ-724),
N-[3,3-di(4-methylphenyl)-2-propenyl]-2-[3-fluoro-4-methylsulfonylamino)-
phenyl]propionamide (4-26, KMJ-908),

N-[3,3-di(4-fluorophenyl)-2-propenyl]-2-[3-fluoro-4-(methylsulfonylamino)-phenyl]propionamide (4-27,SH-135),
N-[2-(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yliden)ethyl]-2-[3-fluoro-4-(methylsulfonylamino)phenyl]propionamide (4-28,SH-199),
N-[2-(3,4-dimethylbenzyl)-3-pivaloxypropyl]-2-[4-(methylsulfonylamino)phenyl]-propionamide (5-1,CHK-512),
N-[2-(4-tert-butylbenzyl)-3-pivaloxypropyl]-2-[4-(methylsulfonylamino)phenyl]-propionamide (5-2,CHK-514),
2-[3-fluoro-4-(methylsulfonylamino)phenyl]-N-[2-(3,4-dimethylbenzyl)-3-pivaloxypropyl]propionamide (5-3,SU-542),
2-[3-fluoro-4-(methylsulfonylamino)phenyl]-N-[2-(4-tert-butylbenzyl)-3-pivaloxypropyl]propionamide (5-4,SU-564),
N-[2-(3,4-dimethylbenzyl)-3-pivaloxypropyl]-2-[3-methoxy-4-(methylsulfonylamino)phenyl]propionamide (5-5,CHK-479),
N-[2-(4-tert-butylbenzyl)-3-pivaloxypropyl]-2-[3-methoxy-4-methylsulfonylamino)phenyl]propionamide (5-6,CHK-499),
N-[2-(3,4-dimethylbenzyl)-3-pivaloxypropyl]-2-[3-chloro-4-(methylsulfonylamino)-phenyl]propionamide (5-7,KNJ-472),
N-[2-(4-tert-butylbenzyl)-3-pivaloxypropyl]-2-[3-chloro-4-(methylsulfonylamino)-phenyl]propionamide (5-8, KMJ-690),
N-[(1R)-1-benzyl-2-(pivaloxy)ethyl]-(2S)-2-[3-fluoro-4-(methylsulfonylamino)-phenyl]propionamide (6-1, SU-730)*
N-[(1S)-1-benzyl-2-(pivaloxy)ethyl]-(2S)-2-[3-fluoro-4-(methylsulfonylamino)-phenyl]propionamide (6-2, SU-634),
N-[(1S)-1-benzyl-2-(pivaloxy)ethyl]-(2R)-2-[3-fluoro-4-methylsulfonylamino)-phenyl]propionamide (6-3, SU-636),
N-[(1R)-1-benzyl-2-(pivaloxy)ethyl]-(2R)-2-[3-fluoro-4-(methylsulfonylamino)-phenyl]propionamide (6-4, SU-728),
N-[(2R)-2-benzyl-3-(pivaloxy)propyl]-(2S)-2-[3-fluoro-4-(methylsulfonylamino)-phenyl]propionamide (6-5, SU-826),

N-[(2S)-2-benzyl-3-(pivaloxy)propyl]-(2S)-2-[3-fluoro-4-(methylsulfonylamino)-phenyl]propionamide (6-6, SU-830),
N-[(2S)-2-benzyl-3-(pivaloxy)propyl]-(2R)-2-[3-fluoro-4-(methylsulfonylamino)-phenyl]propionamide (6-7, SU-838),
N-[(2R)-2-benzyl-3-(pivaloxy)propyl]-(2R)-2-[3-fluoro-4-(methylsulfonylamino)-phenyl]propionamide (6-8, SU-818),
N-[(2R)-2-(4-tert-butyl)benzyl-3-(pivaloxy)propyl]-(2S)-2-[3-fluoro-4-(methylsulfonylamino)phenyl]propionamide (6-9, MK-271),
N-[(2S)-2-(4-tert-butyl)benzyl-3-(pivaloxy)propyl]-(2S)-2-[3-fluoro-4-(methylsulfonylamino)phenyl]propionamide (6-10, MK-272),
N-[(2S)-2-(4-tert-butyl)benzyl-3-(pivaloxy)propyl]-(2R)-2-[3-fluoro-4-(methylsulfonylamino)phenyl]propionamide (6-11, MK-450),
N-[(2R)-2-(4-tert-butyl)benzyl-3-(pivaloxy)propyl]-(2R)-2-[3-fluoro-4-(methylsulfonylamino)phenyl]propionamide (6-12, MK-452),
N-[(2R)-2-(4-tert-butyl)benzyl-3-(pivaloxy)propyl]-(2S)-2-[3-chloro-4-(methylsulfonylamino)phenyl]propionamide (6-13, MK-453),
N-[(2S)-2-(4-tert-butyl)benzyl-3-(pivaloxy)propyl]-(2S)-2-[3-chloro-4-(methylsulfonylamino)phenyl]propionamide (6-14, MK-451),
2-[3-fluoro-4-(methylsulfonylamino)phenyl]-2-methylpropionic acid (7-4, CHK-624),
2-(4-(methylsulfonylamino)phenyl)-2-methylpropionic acid (8-11),
2-[3-methoxy-4-(methylsulfonylamino)phenyl]-2-methylpropionic acid (8-12),
N-[2-(3, 4-dimethylbenzyl)-3-pivaloxypropyl]-2-[4-(methylsulfonylamino)phenyl]-2-methylpropionamide (9-1, CHK-520),
N-[2-(3,4-dimethylbenzyl)-3-pivaloxypropyl]-2-[3-fluoro-4-(methylsulfonylamino)-phenyl]-2-methylpropionamide (9-2, CHK-543),
N-[2-(3,4-dimethylbenzyl)-3-pivaloxypropyl]-2-[3-methoxy-4-(methylsulfonylamino)phenyl]-2-methylpropionamide (9-3, CHK-493),
N-[3-(3,4-dimethylphenyl)propyl]-2-[4-(methylsulfonylamino)phenyl]-2-methylpropionamide (9-4, CHK-591),

N-[3-(3,4-dimethylphenyl)propyl]-2-[3-fluoro-4-(methylsulfonylamino)phenyl]-2-methylpropionamide (9-5, CHK-656),
N-[3-(3,4-dimethylphenyl)propyl]-2-[3-methoxy-4-(methylsulfonylamino)phenyl]-2-methylpropionamide (9-6, CHK-600),
N-(4-tert-butylbenzyl)-2-[4-(methylsulfonylamino)phenyl]-2-methylpropionamide (9-7, CHK- 715),
N-(4-tert-butylbenzyl)-2-[3-fluoro-4-(methylsulfonylamino)phenyl]-2- methylpropionamide (9-8, CHK-655),
N-(4-tert-butylbenzyl)-2-[3-methoxy-4-(methylsulfonylamino)phenyl]-2-methylpropionamide (9-9),
1-[3-fluoro-4-(methylsulfonylamino)phenyl]cyclopropane carboxylic acid (10-5),
1-[4-(methylsulfonylamino)phenyl]cyclopropane carboxylic acid (11-7, CHK-530),
1-[3-methoxy-4-(methylsulfonylamino)phenyl]cyclopropane carboxylic acid (11-8),
N-[2-(3,4-dimethylbenzyl)-3-pivaloxypropyl]-1-[4-(methylsulfonylamino)phenyl]cyclopropane carboxamide (12-1, CHK-533),
N-[2-(3,4-dimethylbenzyl)-3-pivaloxypropyl]-1-[3-fluoro-4-(methylsulfonylamino)-phenyl]cyclopropane carboxamide (12-2, CHK-538),
N-[2-(3,4-dimethylbenzyl)-3-pivaloxypropyl]-1-[3-methoxy-4-(methylsulfonylamino)phenyl]cyclopropane carboxamide (12-3, CHK-541),
N-[3-(3,4-dimethylphenyl)propyl]-1-[4-(methylsulfonylamino)phenyl]-cyclopropane carboxamide (12-4, CHK-590),
N-[3-(3,4-dimethylphenyl)propyl]-1-[3-fluoro-4-(methylsulfonylamino)phenyl]-cyclopropane carboxamide (12-5),
N-[3-(3,4-dimethylphenyl)propyl]-1-[3-methoxy-4-(methylsulfonylamino)phenyl]-cyclopropane carboxamide (12-6, CHK-632),
N-(4-tert-butylbenzyl)-1-[4-(methylsulfonylamino)phenyl]cyclopropane carboxamide (12-7, CHK-719),
N-(4-tert-butylbenzyl)-1-[3-fluoro-4-(methylsulfonylamino)phenyl]cyclopropane carboxamide (12-8, CHK-659), and
N-(4-tert-butylbenzyl)-1-[3-methoxy-4-(methylsulfonylamino)phenyl]cyclopropane carboxamide (12-9, CHK-718).

18. (previously presented) A compound according to claim 15, corresponding to formula (III), or a pharmaceutically acceptable salt or an isomer thereof:



wherein

R₁ to R₄ is independently hydrogen, halogen, cyano group, nitro group, lower alkyl amine, lower alkoxy group having 1 to 3 carbon atoms, carboxylic acid, hydroxamic acid, alkyl ester group having 1 to 6 carbon atoms, alkyl amide group having 1 to 6 carbon atoms, benzylamide group, or a five or six-member heterocyclic ring, provided that all of R₁ to R₄ are not hydrogen atoms simultaneously; and

R₅ and R₆ are independently a hydrogen, hydroxyl group, amino group, straight or branched alkyl group having 1 to 6 carbon atoms, cycloalkyl group having 1 to 6 carbon atoms, or a phenyl or benzyl group optionally substituted with at least one substituent selected from the group consisting of halogen atom, amine group and alkyl group having 1 to 6 carbons, provided that both of R₅ and R₆ are not a hydrogen atom simultaneously.

19. (previously presented) A compound according to claim 18, wherein said compound is selected from the group consisting of:

N-(4-tert-butylbenzyl)-N'-{1-[3-fluoro-4-(methylsulfonylamino)phenyl]ethyl}thiourea (15-1, LJO-328),

N-(4-tert-butylbenzyl)-N'-{1-[3-chloro-4-(methylsulfonylamino)phenyl]ethyl}thiourea (15-2, CHK-992),

N-(4-tert-butylbenzyl)-N'-{1-[3-methoxy-4-(methylsulfonylamino)phenyl]ethyl}thiourea (15-3, CHK-575),

N-(4-tert-butylbenzyl)-N'-{1-[3-(methoxycarbonyl)-4-(methylsulfonylamino)-phenyl]ethyl}thiourea (15-4, YHS-187),

N-(4-tert-butylbenzyl)-N'-{1-[3-carboxy-4-(methylsulfonylamino)phenyl]ethyl}thiourea (15-5, YHS-209),

N-(4-tert-butylbenzyl)-N'-{(1R)-1-[4-(methylsulfonylamino)phenyl]ethyl}thiourea (16-5, SU-388),

N-(4-tert-butylbenzyl)-N'-{(1S)-1-[4-(methylsulfonylamino)phenyl]ethyl}thiourea (16-6, SU-400),

N-(4-tert-butylbenzyl)-N'-{(1R)-1-[3-fluoro-4-(methylsulfonylamino)phenyl]ethyl}thiourea (17-3, CJU-032),

N-(4-tert-butylbenzyl)-N'-{(1S)-1-[3-fluoro-4-(methylsulfonylamino)phenyl]ethyl}thiourea (17-6, CJU-039),

N-[(2R)-2-benzyl-3-(pivaloyloxy)propyl]-N'-{(1R)-1-[4-(methylsulfonylamino)-phenyl]ethyl}thiourea (18-1, MK-229),

N-[(2S)-2-benzyl-3-(pivaloyloxy)propyl]-N'-{(1R)-1-[4-(methylsulfonylamino)-phenyl]ethyl}thiourea (18-2, MK-202),

N-[(2R)-2-benzyl-3-(pivaloyloxy)propyl]-N'-1(1S)-1-[4-(methylsulfonylamino)-phenyl]ethyl}thiourea (18-3, MK-230),

N-[(2S)-2-benzyl-3-(pivaloyloxy)propyl]-N'-{(1S)-1-[4-(methylsulfonylamino)-phenyl]ethyl}thiourea (18-4, MK-228),

N-[2-(3,4-dimethylbenzyl)-3-(pivaloyloxy)propyl]-N'-{1-[4-(methylsulfonylamino)-phenyl]ethyl}thiourea (18-5, LJO-388),

N-[2-(3,4-dimethylbenzyl)-3-(pivaloyloxy)propyl]-N'-{(1R)-1-[4-(methylsulfonylamino)phenyl]ethyl}thiourea (18-6, SU-472),

N-[(2R)-2-(3,4-dimethylbenzyl)-3-(pivaloyloxy)propyl]-N'-{(1R)-1-[4-(methylsulfonylamino)phenyl]ethyl}thiourea (18-7, SU-512),

N-[(2S)-2-(3,4-dimethylbenzyl)-3-(pivaloyloxy)propyl]-N'-{1-[4-(methylsulfonylamino)phenyl]ethyl}thiourea (18-8),

N-[2-(4-tert-butylbenzyl)-3-(pivaloyloxy)propyl]-N'-{1-[4-(methylsulfonylamino)-phenyl]ethyl}thiourea (18-9, LJO-401),

N-[2-(4-*tert*-butylbenzyl)-3-(pivaloyloxy)propyl]-N'-{1(R)-[4-(methylsulfonylamino)phenyl]ethyl}thiourea (18-10, MK-296),
N-[2(R)-(4-*tert*-butylbenzyl)-3-(pivaloyloxy)propyl]-N'-{1(R)-[4-(methylsulfonylamino)phenyl]ethyl}thiourea (18-11, MK-334),
N-[2(S)-(4-*tert*-butylbenzyl)-3-(pivaloyloxy)propyl]-N'-{1(R)-[4-(methylsulfonylamino)phenyl]ethyl}thiourea (18-12, MK-298),
N-[2-(3,4-(dimethylbenzyl)-3-(pivaloyloxy)propyl]-N'-{1-[3-fluoro-4-(methylsulfonylamino)phenyl]ethyl}thiourea (18-13, LJO-344),
N-[2-(4-*tert*-butylbenzyl)-3-(pivaloyloxy)propyl]-N'-{1-[3-fluoro-4-(methylsulfonylamino)phenyl]ethyl}thiourea (18-14, LJO-366),
N-[(2R)-3-phenyl-1-pivaloyloxy-2-propyl]-N'-[(R)- α -methyl-4-(methylsulfonylamino)benzyl]thiourea (19-13, SU-692),
N-[(2S)-3-phenyl-1-pivaloyloxy-2-propyl]-N'-[(R)- α -methyl-4-(methylsulfonylamino)benzyl]thiourea (19-14, SU-704),
N-[(2R)-3-phenyl-1-pivaloyloxy-2-propyl]-N'-[(S)- α -methyl-4-(methylsulfonylamino)benzyl]thiourea (19-15, SU-720),
N-[(2S)-3-phenyl-1-pivaloyloxy-2-propyl]-N'-[(S)- α -methyl-4-(methylsulfonylamino)benzyl]thiourea (19-16, SU-710),
N-(4-*tert*-butylbenzyl)-N'-{1-4-(methylsulfonylamino)-3-fluorophenyl} propyl}thiourea (20-12, LJO-399),
N-(4-*tert*-butylbenzyl)-N'-{1-[4-(methylsulfonylamino)-3-fluorophenyl]-2-methylpropyl}thiourea (20-13, LJO-402),
N-(4-*tert*-butylbenzyl)-N'-{[4-(methylsulfonylamino)-3-fluorophenyl](phenyl)-methyl}thiourea (20-14, LJO-403),
N-4-*tert*-butylbenzyl)-N'-{1-[4-(methylsulfonylamino)-3-fluorophenyl]-2-phenylethyl}thiourea (20-15, LJO-395),
N-(4-*tert*-butylbenzyl)-N'-{1-methyl-1-[4-(methylsulfonylamino)phenyl]-ethyl}thiourea (21-7, CHK-593),
N-(4-*tert*-butylbenzyl)-N'-{1-methyl-1-[3-fluoro-4-(methylsulfonylamino)-phenylethyl}thiourea (21-8, CHK-660),


N-(4-*tert*-butylbenzyl)-N'-{1-methyl-1-[3-methoxy-4-methylsulfonylamino)phenyl]-ethyl}thiourea (21-9, CHK-629),

N-(4-*tert*-butylbenzyl)-N'-{1-[4-(methylsulfonylamino)phenyl]-cyclopropyl}-thiourea (22-7, CHK-579),

N-(4-*tert*-butylbenzyl)-N'-{1-[3-fluoro-4-(methylsulfonylamino)phenyl]-cyclopropyl}thiourea (22-8), and

N-(4-*tert*-butylbenzyl)-N'-{1-[3-methoxy-4-(methylsulfonylamino)phenyl]-cyclopropyl}thiourea (22-9, CHK-631).

~~21~~ 20. (currently amended) A compound according to claim 15, corresponding to formula (IV), or a pharmaceutically acceptable salt or isomer thereof :



wherein,

R₁ to R₄ is independently a hydrogen, halogen atom, cyano group, nitro group, lower alkyl amine, lower alkoxy group having 1 to 3 carbon atoms, carboxylic acid, hydroxamic acid, alkyl ester group having 1 to 6 carbon atoms, alkyl amide group having 1 to 6 carbon atoms, benzylamide group, or five or six-member heterocyclic ring; and


R₅ and R₆ are independently a hydrogen, hydroxyl group, amino group, straight or branched alkyl group having 1 to 6 carbon atoms, cycloalkyl group having 1 to 6 carbon atoms, or a phenyl or benzyl group optionally substituted with at least one substituent selected from the group consisting of a halogen atom, amine group and alkyl group having 1 to 6 carbons, provided that both of R₅ and R₆ are not hydrogen atoms simultaneously.

21. (previously presented) A compound according to claim 20, wherein said compound is

N-(4-*tert*-butylbenzyl)-N'-1-[4-(methylsulfonylamino)phenyl]ethyl}urea (23-1, MK-82), or

N-(4-*tert*-butylbenzyl)-N'-1-[3-fluoro-4-(methylsulfonylamino)phenyl]ethyl}- urea (23-2, MK-205).

22. (previously presented) A compound according to claim 15, corresponding to formula (V), or a pharmaceutically acceptable salt or isomer thereof :



wherein,

R₁ to R₄ is independently a hydrogen, halogen atom, cyano group, nitro group, lower alkyl amine, lower alkoxy group having 1 to 3 carbon atoms, carboxylic acid, hydroxamic acid, alkyl ester group having 1 to 6 carbon atoms, alkyl amide group having 1 to 6 carbon atoms, benzylamide group, or a five or six-member heterocyclic ring; and

R₅ and R₆ are independently a hydrogen, hydroxyl group, amino group, straight or branched alkyl group having 1 to 6 carbon atoms, cycloalkyl group having 1 to 6 carbon atoms, or a phenyl or benzyl group optionally substituted with at least one substituent selected from the group consisting of halogen atoms, amine groups and alkyl groups having 1 to 6 carbons, provided that both of R₅ and R₆ are not hydrogen atoms simultaneously.

23. (previously presented) A compound according to claim 22, wherein said compound is selected from the group consisting of:

N-{1-[3-fluoro-4-(methylsulfonylamino)phenyl]ethyl}-3-(4-*tert*-butylphenyl)-acetamide (24-1, KMJ-586),

N-1-[3-fluoro-4-(methylsulfonylamino)phenyl]ethyl}-3-(4-tert-butylphenyl)-propanamide (24-2, KMJ-552),
N-{1-[3-fluoro-4-(methylsulfonylamino)phenyl]ethyl}-3-(4-tert-butylphenyl)-2-propanamide (24-3, KMJ-570),
N-{1-[3-fluoro-4-(methylsulfonylamino)phenyl]ethyl}-3-(3,4-dimethylphenyl)-propanamide (24-4, CHK-602),
N-1-[3-fluoro-4-(methylsulfonylamino)phenyl]ethyl}-3-(3,4-dimethylphenyl)-2-propanamide (24-5, CHK-651),
N-1-[3-fluoro-4-(methylsulfonylamino)phenyl]ethyl}-3-(3,4-dimethylphenyl)propanamide (24-6, CHK-534),
N-{1-[3-fluoro-4-(methylsulfonylamino)phenyl]ethyl}-3-(4-chlorophenyl)-2-propanamide (24-7, KMJ-558), and
N-{1-[3-fluoro-4-(methylsulfonylamino)phenyl]ethyl}-3-(3,4-dimethylphenyl)-butanamide (24-8, CHK-647).

24. (previously presented) A compound according to claim 15, wherein R₁ to R₄ is independently a hydrogen, halogen atom, cyano group, nitro group, lower alkyl amine, lower alkoxy group having 1 to 3 carbon atoms, carboxylic acid, hydroxamic acid, alkyl ester group having 1 to 6 carbon atoms, alkyl amide group having 1 to 6 carbon atoms, benzylamide group, or a five or six-member heterocyclic ring.

25. (previously presented) A compound according to claim 15, wherein R₅ and R₆ are independently a hydrogen, hydroxyl group, amino group, straight or branched alkyl group having 1 to 6 carbon atoms, cycloalkyl group having 1 to 6 carbon atoms, or a phenyl or benzyl group optionally substituted with at least one substituent selected from the group consisting of a halogen atom, amine group or an alkyl group having 1 to 6 carbons.

26. (previously presented) A pharmaceutical composition comprising a compound according to claim 15 as an active ingredient in an effective vanilloid receptor

antagonizing amount, together with a pharmaceutically acceptable carrier or diluent.

27. (previously presented) A method of treating acute pain, chronic pain, neuropathic pain, post-operative pain, migraine, arthralgia, neuropathies, nerve injury, diabetic neuropathy, neurodegeneration, neurotic skin disorder, stroke, urinary bladder hypersensitiveness, irritable bowel syndrome, a respiratory disorder, irritation of skin, eye or mucous membrane, fervescence, coughing, stomach-duodenal ulcer, or inflammatory bowel disease caused by the vanilloid receptor antagonistic activity, in a patient suffering therefrom, said method comprising administering to said patient a pharmaceutically effective amount of at least one compound according to claim 15.

28. (previously presented) Method of treating or inhibiting pain or inflammation, in a patient suffering therefrom, said method comprising administering to said patient a pharmaceutically effective amount of at least one compound according to claim 15.

29. (currently amended) The ~~pharmaceutical composition~~ method according to claim 27, wherein the respiratory disorder is asthma ~~or method of treating asthma~~ or chronic obstructive pulmonary disease ~~—, in a patient suffering therefrom, said method comprising administering to said patient a pharmaceutically effective amount of at least one compound according to claim 15.~~